Keros Therapeutics (NASDAQ:KROS – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.
Profitability
This table compares Keros Therapeutics and CRISPR Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Keros Therapeutics | -256.60% | -21.40% | -19.79% |
| CRISPR Therapeutics | -3,368.72% | -24.39% | -18.25% |
Analyst Ratings
This is a breakdown of current recommendations for Keros Therapeutics and CRISPR Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Keros Therapeutics | 1 | 4 | 4 | 0 | 2.33 |
| CRISPR Therapeutics | 1 | 7 | 9 | 2 | 2.63 |
Volatility & Risk
Keros Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.
Insider and Institutional Ownership
71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 12.6% of Keros Therapeutics shares are held by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Keros Therapeutics and CRISPR Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Keros Therapeutics | $244.06 million | 0.92 | $87.01 million | ($3.70) | -3.05 |
| CRISPR Therapeutics | $3.51 million | 1,360.55 | -$581.60 million | ($4.76) | -10.38 |
Keros Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Keros Therapeutics beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.
About Keros Therapeutics
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
